Podcasts about md anderson cancer center

Dr. Jennifer Wargo is an Associate Professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center and a Stand Up To Cancer researcher. Jennifer is a physician scientist, and this means she splits her time between providing care to patients and doing research to find better ways of treating disease. Specifically, Jennifer performs surgeries and treats patients one day each week. She spends the rest of her week studying how to better treat patients with cancer and how cancer may ultimately be prevented. When she's not doing research or treating patients, Jennifer enjoys spending quality time with her family. Some of their favorite activities include going for walks, biking, hiking, and visiting the beach. Jennifer also likes to explore her creative side through art and photography, as well as to be active through running, biking, yoga, and surfing. She received her A.S. degree in nursing and B.S. degree in biology from Gwynedd-Mercy College. Afterwards, Jennifer attended the Medical College of Pennsylvania where she earned her M.D. Jennifer completed her Clinical Internship and Residency in General Surgery at Massachusetts General Hospital. Next, Jennifer was a Research Fellow in Surgical Oncology at the University of California, Los Angeles. She then accepted a Clinical Residency in General Surgery at Massachusetts General Hospital. From 2006-2008, Jennifer was a Clinical Fellow in Surgical Oncology at the National Cancer Institute of the National Institutes of Health. She then served on the faculty at Massachusetts General Hospital and Harvard University. In 2012, Jennifer received her MMSc. degree in Medical Science from Harvard University. Jennifer joined the faculty at The University of Texas MD Anderson Cancer Center in 2013. She is Board Certified by the American Board of Surgery, and she has received numerous awards and honors throughout her career. These have included the R. Lee Clark Prize and Best Boss Award from the MD Anderson Cancer Center, the Rising STARS and The Regents' Health Research Scholars Awards from the University of Texas System, the Outstanding Young Investigator and Outstanding Investigator Awards from the Society for Melanoma Research, as well as a Stand Up To Cancer Innovative Research Grant for her microbiome work. She has also received other awards for excellence in teaching, research, and patient care. In our interview, Jennifer shares more about her life and science.

On Thursday's show: We learn about a $150 million donation that will create the Kinder Children's Cancer Center, a new initiative to fight childhood cancer at MD Anderson Cancer Center and Texas Children's Hospital. The gift is one of the largest such donations in the history of the Texas Medical Center and one of the largest ever given to a pediatric hospital in the country.Also this hour: Comedian Ramy Youssef performs Friday night at House of Blues, and he has a new animated series on Amazon Prime called #1 Happy Family USA! We revisit a 2019 conversation with him about how he got into comedy and about how much of his standup material and work on television has revolved around the experience of growing up Muslim in America.Then, a Houston mother lost her parental rights to her children for life because of allegations her ex-husband made in court. We learn why the Texas Supreme Court unanimously overturned that ruling and what it means for how protective orders are issued here.And Laura Walker visits a farm run by the Socialites Riding Network, a Black-owned nonprofit that teaches sustainable agriculture and an appreciation for animals.

Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually. Click here to listen to module 2 of this podcast series: [link] Click here to claim your CME/NCPD credit: [link]

In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments. Click here to go back and listen to module 1 of this podcast series: [link] Click here to claim your CME/NCPD credit: [link]

Dr. Debraj Shome is a leading facial plastic and cosmetic surgeon, co-founder of The Esthetic Clinics, and a consultant at top hospitals like Breach Candy and Apollo Spectra in Mumbai. Recognized among the world's best plastic surgeons, he holds multiple degrees, including MBBS, DNB, FRCS (Glasgow), and an MBA in Healthcare Management from Vanderbilt University. He has trained at prestigious institutions like LV Prasad Eye Institute and MD Anderson Cancer Center. With expertise in facial reconstructive and oculoplastic surgery, he continues to advance cutting-edge surgical techniques in India.In this episode, Vinamre and Dr. Debraj talk about:- The science behind facial symmetry, beauty standards across different races, and how plastic surgery aims to achieve the ideal look.- Differences between plastic and cosmetic surgery, government regulations, and why many surgeons shift their focus to aesthetics.- Popular and controversial procedures like rhinoplasty, deep-plane facelifts, Botox, liposuction, and gender reassignment surgeries, along with their costs and risks in India.- Unusual trends, celebrity influence, secrecy around procedures, and societal perceptions of plastic surgery.- In the last segment, ethnic conflicts in the '90s, his family's migration from Bangladesh to India, the Indian flag in the Northeast, and the impact of generational wealth and ethnic cleansing.From facial symmetry and cosmetic trends to surgical risks and costs, this episode dives deep into the world of plastic surgery.Timestamps:====================================================================This is the official channel for Dostcast, a podcast by Vinamre Kasanaa. Connect with meLinkedIn: https://www.linkedin.com/in/vinamre-kasanaa-b8524496/Instagram: https://www.instagram.com/vinamrekasanaa/Twitter: https://twitter.com/VinamreKasanaaDostcast on Instagram: https://www.instagram.com/dostcast/Dostcast on Twitter: https://twitter.com/dostcastDostcast on Facebook: https://www.facebook.com/profile.php?id=61557567524054====================================================================Contact UsFor business inquiries: dostcast@egiplay.com

In this episode, Dr. Jennifer Bickel, Chief Wellness Officer at MD Anderson Cancer Center, shares insights into how she's working to build a system-wide culture of well-being. She discusses the importance of operational changes, the development of a Wellness Institute, and tailored strategies to support oncology staff facing emotional and systemic challenges.

For this episode, we're going back to a familiar villain from podcast-past because  unfortunately, healthcare villains have a habit of staying relevant. This is a guy who made his fame by cozying up to Oprah while schilling diet pills, supplements, and medical conspiracy theories – it's Doctor Oz, who is now Trump's nominee for Director of the Center for Medicare and Medicaid Services. That's right, the man who has previously claimed that there are deadly levels of arsenic in apple juice, that most olive oil is fake, that “Reparative Therapy” can cure homosexuality, and that hydroxychloroquine cures COVID, is pretty close to running our largest public health systems. Today I'm talking with Dr. Diljeet Singh of Physicians for a National Health program about what that means for you and the country at large, and how we can do something about it!  NOTE: At the Medicare for All Podcast, we've had a brief, unplanned hiatus due to pesky technical issues – and the fact that Trump is keeping us busy in our organizing work – but we are very excited to be back! I'm flying solo right now while my regular cohost Ben is saving the environment at his 9 to 5 organizing job, but that feels like important work as well, so we're going to give him a pass and send him our love! https://www.youtube.com/live/3ZUE4sOTI_g?si=WGg97KnP-UxktIsu Our guest for this episode was the brilliant Dr. Diljeet Singh! She's a women's health advocate, an integrative gynecologic oncologist, and the President of Physicians for a National Health Program. Dr. Singh received her medical degree from Northwestern University and her master's degree from the Harvard School of Public Health. She completed an obstetrics and gynecology residency at Johns Hopkins and a gynecologic oncology fellowship at the MD Anderson Cancer Center. She completed her doctoral degree in public health on cost analysis at the University of Texas School of Public Health and an associate fellowship in integrative medicine at the University of Arizona. Dr. Singh and our friends at Physicians for a National Health Program are going all out to let folks know about the serious danger Dr. Oz poses to our national health! Check out the videos from their Dr. Oz Shadow Hearing below: https://youtube.com/playlist?list=PLO8yDO3B42TdHs6GC-PcLez2ZHfZ4CfTN&si=Q3YMJR1IEvr9uHX1 Even though it is likely that the Senate will make it official later this month, as of April 1st, Dr. Oz still hasn't been confirmed, so if you're listening to this in the next couple weeks, you may still be able to call your Senators to ask them to come to their senses! Reach their offices through the Capitol Hill switchboard: (202) 224-3121. Follow & Support the Pod! Don't forget to like this episode and subscribe to The Medicare for All Podcast on Apple Podcasts, Google Podcasts, or your favorite podcast platform! This show is a project of the Healthcare NOW Education Fund! This show is a project of the Healthcare-NOW Education Fund! If you want to support our work, you can donate at our website, healthcare-now.org.

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.htmlAbstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.htmlAbstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.htmlVenetoclax resistance mechanismshttps://pubmed.ncbi.nlm.nih.gov/39478230/FLAG-GO vs FLAG-IDA https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine CPX-351: Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.htmlAbstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.htmlMenin Inhibitors Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.htmlAbstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.htmlAbstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.htmlAbstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html FLT3 inhibitors Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html MDS Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html ATRA in MDS:  https://ash.confex.com/ash/2024/webprogram/Paper200433.html  

Host: Jennifer Caudle, DO Guest: Naval Daver, MD Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it's also associated with more proliferative disease that's resistant to standard therapies. Given its prevalence and potential implications, a number of different CD123-targeting approaches are under investigation, including antibody-drug conjugates, bi-specific antibodies, fusion protein, and CAR T-cell therapy. In light of these new approaches, Dr. Jennifer Caudle and Dr. Naval Daver discuss the importance of targeting CD123 in AML. Dr. Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center in Houston.

Early detection is critical for improving cancer survival rates, yet pancreatic cancer remains challenging to detect. A recent breakthrough from Mayo Clinic researchers offers new hope. Artificial intelligence models demonstrate the potential to detect pancreatic cancer earlier and with remarkable accuracy. Learn more about this life-changing innovation in early cancer detection. Featured experts include Ajit Goenka, M.D., radiologist and professor of radiology at Mayo Clinic's Comprehensive Cancer Center and Suresh Chari, M.D., professor, Department of Gastroenterology, Hepatology, and Nutrition in the Division of Internal Medicine at MD Anderson Cancer Center.Get the latest health information from Mayo Clinic's experts, subscribe to Mayo Clinic's newsletter for free today:  https://mayocl.in/3EcNPNc

Up for the Fight: How to Advocate for Yourself as You Battle Cancer―from a Five-Time Survivor by Bill C. Potts Amazon.com Billcpotts.com The guide endorsed by MD Anderson Cancer Center and the Mayo Clinic, and used by Leukemia and Lymphoma Society and Multiple Myeloma Research Foundation patients. Imagine a road map for the entire cancer journey, for both patients and their loved ones. That's what this book is. Think What to Expect When You're Expecting, but for navigating the complexities of a cancer diagnosis, its treatment, and beyond. Up for the Fight empowers you to take control of your cancer journey with advice from five-time cancer survivor Bill C. Potts. Learn to be your own advocate, build the right care team, and prioritize your emotional and mental well-being. Discover practical tips for comfortable treatment days, side effect management, and understanding test results. Gain valuable insights on diet, exercise, and staying active while navigating the impacts of treatment and the disease on your immune system. Special sections offer guidance for supporting loved ones with cancer, facing mortality with peace, and realigning your priorities to truly live your life to the fullest. This book equips you with the knowledge and tools you need to fight this battle, all from the perspective of a tenacious cancer veteran.About the author Bill C. Potts is a motivational speaker, creative business leader, energetic community builder, and dedicated father and husband. A five-time cancer survivor, he pursues life with the utmost passion and drive. While his kids say he's “sometimes slightly embarrassing,” they also admit he's the “toughest man we have ever met.” He loves his job and wakes up each morning expecting an A+ day—because every day is an A+ day, no matter the circumstances. An IRONMAN triathlete and the co-founder of marketing agency Remedy 365, Bill lives in St. Petersburg, Florida, with his wife, Kim, and their dog Pippa.

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, CTMC, is challenging the status quo to achieve this and get them to patients. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine aiming to advance novel scientific breakthroughs into medicines developed rapidly and robustly to - ultimately - end cancer. Taking learnings from the monoclonal antibody field to come up with a fit-for-purpose solution, Bock discusses his work in the joint venture between the MD Anderson Cancer Center and biopharmaceutical manufacturer Resilience – combining industrial manufacturing and development capabilities with the work of an academic medical centre. CTMC's is a “patient adjacent” manufacturing model – crucial when it comes to developing personalised therapies (especially when dealing with living cells), and Bock explains how patient-centric approaches streamline manufacturing processes, improve efficacy, and allow for that personalised treatment approach, particularly when the supply chain is local. You can listen to episode 168a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

In this episode of the INS Infusion Room, host Derek Fox engages with Jennifer Acelajado and Hammam Ahmed, both clinical outcome specialists at MD Anderson Cancer Center, Houston, Texas, to discuss the critical topic of catheter-to-vein ratio (CVR) in vascular access nursing. They share their extensive backgrounds in nursing, the importance of patient education, and the role of their vascular access team in enhancing patient experience through effective practices. The conversation delves into their research on CVR, comparing different methodologies and definitions, and emphasizes the need for clear standards in practice to improve patient outcomes. The episode concludes with an invitation to the upcoming INS annual meeting, where they will present their findings.

In this episode, Dr. Michelle F. DeVeau, Director of the Leadership Institute, and Dr. Amanda Woods, Associate Leadership Institute Analyst at MD Anderson Cancer Center, discuss their innovative coaching programs, the impact on leadership retention and development, and how data-driven strategies are shaping the future of coaching in healthcare organizations.

Dr Akila Viswanathan speaks with Dr Robert Coppes from The University Medical Center Groningen, Dr David Jaffray from MD Anderson Cancer Center and Dr Helen McNair from The Royal Marsden NHS Foundation Trust Institute of Cancer Research to look ahead to the future of radiation oncology as they discuss how to improve decision making, incorporating artificial intelligence, adapt to new training methods, improve safety and sustainability and much more for Seminars in Radiation Oncology.

Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX Recorded on January 21, 2025 Jason Westin, M.D., MS, FACP Professor, Department of Lymphoma & Myeloma Lead, Lymphoma & Myeloma Service Line Director, Lymphoma Clinical Research Section Chief, Aggressive and Indolent Lymphoma MD Anderson Cancer Center Houston, TX In this episode, Dr. Jason Westin from MD Anderson Cancer Center in Houston, Texas explores CAR T-cell therapy, covering both current and emerging indications. He highlights the educational needs of patients and caregivers, as well as the essential role of community and academic collaboration before and after treatment. Dr. Westin also discusses the use of minimal/measurable residual disease (MRD) in treatment planning, future directions of CAR-T, and ongoing clinical trials. Tune in to stay up-to-date on the latest advancements in CAR T-cell therapy! This episode is supported by Allogene Therapeutics, Bristol Myers Squibb, Johnson& Johnson & Legend Biotech, and Kite, a Gilead Company.

In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed:  1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. https://pubmed.ncbi.nlm.nih.gov/38820078/ 2. 5-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/26837842/ 3. 10-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/33414482/ 4. 10-year follow-up of CML-IV RCT (imatinib): https://pubmed.ncbi.nlm.nih.gov/25676422/ 5. MD Anderson data on low-dose dasatinib (50 mg): https://pubmed.ncbi.nlm.nih.gov/36054032/https://pubmed.ncbi.nlm.nih.gov/31553487/ 6. CML: 2025 update on diagnosis, therapy, and monitoring: https://pubmed.ncbi.nlm.nih.gov/39093014/ 

RUSH MD Anderson Cancer Center offers leading-edge treatments for GI cancers, including targeted therapies, immunotherapy, chemotherapy, and minimally invasive surgical options. Our multidisciplinary team of medical oncologists, gastroenterologists, surgical oncologists, colorectal surgeons and interventional radiologists work together to provide our patients with tailored treatment plans to each patient's specific diagnosis and needs. Audrey Kam, MD, is the director of GI medical oncology at RUSH MD Anderson, as well as the research director of GI medical oncology at RUSH MD Anderson. She specializes in treating gastrointestinal cancers including colorectal, esophageal, gastrointestinal, liver, pancreatic and stomach cancers. Sam Pappas, MD, is the Division Chief of Surgical Oncology at Rush University Medical Center. He specializes in treating upper abdominal cancers, including ones in the esophagus, stomach, pancreas, liver and bile duct. “We love collaborating in immediate proximity to each other within RUSH MD Anderson. This helps to ensure coordinated, multidisciplinary discussions that are patient-focused,” explains Dr. Pappas.

In this episode of Bladder Cancer Matters, host Rick Bangs is joined by the esteemed Dr. Ashish Kamat of MD Anderson Cancer Center to dive into the often-overlooked world of histologic subtypes, or variants, of bladder cancer. These rare subtypes can significantly alter how bladder cancer behaves and responds to treatment. Dr. Kamat breaks down the science behind these variants in a way that's both accessible and empowering for patients, offering crucial insights into why understanding your specific diagnosis matters. From the differences between common urothelial cancer and variants to the critical questions patients should ask their doctors, this conversation is packed with valuable information for anyone navigating a bladder cancer journey.

A typical human lifespan is approximately three billion heartbeats in duration. Lasting that long requires not only intrinsic stability, but an impressive capacity for self-repair. Nevertheless, things do occasionally break down, and cancer is one of the most dramatic examples of such breakdown. Given that the body is generally so good at protecting itself, can we harness our internal security patrol - the immune system - to fight cancer? This is the hope of Nobel Laureate James Allison, who works on studying the structure and behavior of immune cells, and ways to coax them into fighting cancer. This approach offers hope of a way to combat cancer effectively, lastingly, and in a relatively gentle way.Support Mindscape on Patreon.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2025/01/27/303-james-p-allison-on-fighting-cancer-with-the-immune-system/James P. Allison received his Ph.D. in biology from the University of Texas at Austin. He is currently Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and Director of the James P. Allison Institute at MD Anderson Cancer Center. He is the subject of the documentary film Jim Allison: Breakthrough. Among his numerous awards are the Breakthrough Prize in Life Sciences and the Nobel Prize in Physiology or Medicine.Web pageNobel Prize citationGoogle Scholar publicationsWikipediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At RUSH MD Anderson Cancer Center, oncologists provide patient-centered, cutting-edge care, such as immunotherapies, targeted therapies and minimally invasive surgeries for the treatment of lung cancer. In addition, RUSH MD Anderson clinicians offer patients access to some of the most innovative clinical trials available nationwide. In this episode, Helen Ross, MD, discusses some of the exciting new clinical trials that Rush is participating in, as well as rising rates of lung cancer in young adults and how to best care for them. Helen Ross, MD, is a thoracic medical oncologist and an expert in the care of patients with cancers of the chest, including lung cancers, mesothelioma and thymic cancers. Dr. Ross is director of research and clinical trials at RUSH MD Anderson. She is also a professor in the Department of Internal Medicine and serves as interim chief of the Division of Hematology, Oncology and Cellular Therapy. “We're only opening clinical trials onsite that are the right fit for our patients. We have an expedited review at RUSH MD Anderson to cut activation time and are working to further reduce that time to bring those trials more quickly to our patients.”

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma. We dived into four key studies: 1.⁠ ⁠AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS). 2.⁠ ⁠Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care. 3.⁠ CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease. 4.⁠ ⁠Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies. Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024! Subscribe to the Oncology Brothers for more updates and expert insights in oncology! Website: http://www.oncbrothers.com/  X/Twitter: https://twitter.com/oncbrothers  Contact us at info@oncbrothers.com

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer. Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting. Key topics include: • Overview of biliary tract cancer and its treatment landscape • Study design and patient characteristics from the HERIZON-BTC-01 trial • Key findings, including overall response rates and duration of response • The importance of HER2 testing and its implications for treatment sequencing • Side effect profiles and management strategies for Zanidatamab • Future directions and ongoing clinical trials Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer. Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the rapidly evolving world of CAR T cell therapy, a groundbreaking treatment for various hematologic malignancies. Joined by experts Dr. Surbhi Sidana from Stanford University and Dr. Jason Westin from MD Anderson Cancer Center, we explore the mechanism of action of CAR T cells, their side effects, and management strategies.   Episode Highlights: Understanding CAR T cell therapy and its application in hematologic malignancies and solid tumors. Mechanism of action: How CAR T cells are engineered to target cancer cells. Acute side effects: Cytokine release syndrome (CRS) and neurotoxicity, including clinical pearls for management. Chronic side effects: Monitoring for infections, cytopenias, and the risk of secondary malignancies. The importance of bridging therapy and managing tumor burden before CAR T treatment. Insights for community oncologists on patient management and communication with CAR T centers.   Join us for an informative discussion that emphasizes the importance of recognizing and managing the unique side effects of CAR T therapy to ensure the best outcomes for patients. Don't forget to check out our other episodes for more insights into recent advances in hematology and oncology!   Subscribe for more discussions on FDA approvals, treatment algorithms, and conference highlights. We are the Oncology Brothers!   Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

The Human Side of Dermatopathology: A Conversation with Dr. Victor PrietoIn this episode, Dr. Victor Prieto, a pathologist and dermatopathologist at MD Anderson Cancer Center, discusses the fallibility of experts, the importance of addressing mistakes in medicine, and the crucial balance of experience and humility in clinical practice. He shares insights into improving patient care by learning from errors, the significance of self-care, and the profound impact of a doctor's work on patients' lives. Dr. Prieto also offers advice on finding mentorship and reinforces the value of passion and dedication in the medical profession.00:00 Introduction and Guest Welcome00:45 The Fallibility of Experts03:07 Addressing Mistakes in Medicine05:46 Work-Life Balance in Medicine07:44 The Rewards of a Medical Career09:39 Final Thoughts and Advice

Dr. Van Morris presents the new evidence-based guideline on systemic therapy for localized anal squamous cell carcinoma. Dr. Morris discusses the key recommendations from the Expert Panel, including recommended radiosensitizing chemotherapy agents, dosing and schedule recommendations, the role of induction chemotherapy and ongoing adjuvant chemotherapy, and considerations for special populations. He emphasizes the importance of this first guideline from ASCO on anal squamous cell carcinoma for both clinicians and patients with stage I-III anal cancer, and ongoing research the panel is looking to for the future. Read the full guideline, “Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline” at www.asco.org/gastrointestinal-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02120 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts, delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Van Morris from MD Anderson Cancer Center, co-chair on “Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.” Thank you for being here today, Dr. Morris. Dr. Van Morris: Thank you for having me. On behalf of our committee who put together the guidelines, I'm really excited to be here and talk with you today. Brittany Harvey: Great. Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Morris, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to jump into the content of this guideline, Dr. Morris, can you provide an overview of both the purpose and the scope of this guideline on stage I to III anal squamous cell carcinoma? Dr. Van Morris: So anal cancer is considered a rare malignancy for patients in the United States and across the world as well. Even though it's not something we see as commonly, for example, as the adjacent colorectal cancer, this still is a cancer that is rising in incidence every year in the United States. And really, despite the presence of the preventative HPV vaccines, which we hope will ultimately prevent and eradicate this cancer, we still expect the incidence to continue to rise in the coming decades before we really start seeing numbers begin to decrease as a result of the vaccine. So this is an alarming trend for which oncologists will continue to see likely more and more cases and new diagnoses every year. So we wanted to review the most recent literature and provide oncologists up to date recommendations for how they can best take care of patients with a new diagnosis of localized anal cancer. Brittany Harvey: Absolutely. I appreciate that background and context to set the stage for this guideline. So then next I'd like to review the key recommendations of this guideline. So starting from the first clinical question, what are the recommended radiosensitizing, doublet or single chemotherapy agents for patients with stage I to III anal cancer? Dr. Van Morris: It's true that really the standard treatment for patients with localized anal cancer has not changed over the last literally half century. When the Nigro regimen was first reported back in 1974, 50 years ago, the standard of care for patients with a new diagnosis of localized anal cancer centers around concurrent chemotherapy and radiotherapy. And we looked at the various randomized control trials and the highest level of evidence which has been reported over the past decades, and really for most patients, the standard of care continues to remain doublet cytotoxic chemotherapy in combination with radiation. We reported that the most commonly, and I think most accepted, regimen here is a combination regimen of 5-FU, intravenous 5-fluorouracil with mitomycin C. And this most commonly is given on a week 1 to 5 regimen. The 5-FU, we recommended a dose of 1000 milligrams per meter squared per day on days 1 to 4 and then on days 29 to 32 of the radiation treatment. And then the mitomycin C, looking at various trials, has been given at a dose of 10 milligrams per meter squared on day 1 and day 29, or alternatively a single dose of mitomycin C at 12 milligrams per meter squared on day 1. I think that the thing that's important for clinicians and patients alike to remember is that this chemotherapy can be very toxic in patients who are undergoing a curative-intent therapy for this diagnosis of localized anal cancer. I think it's just important for oncologists to be watching closely the blood counts for the patients to make sure that the myelosuppression doesn't get too bad. And then in select cases, if that is the case, when the oncologist opts to go for the day 1 and day 29 dosing, it may be prudent, if the myelosuppression is too excessive, to consider withholding that day 29 dose. Brittany Harvey: Great. Thank you for providing those recommendations along with some of those dosing and the schedule recommendations from the expert panel. So are there any other alternate dose or schedule recommendations from the expert panel? Dr. Van Morris: Yeah, but I think that we saw with the ACT II data that was a randomized trial that was done out of the UK that compared 5-FU mitomycin with 5-FU cisplatin as two different doublet cytotoxic regimens, that overall outcomes were very similar between the two regimens in terms of curative outcomes for patients treated whether 5-FU mitomycin or 5-FU cisplatin. So certainly there is evidence supporting the use of cisplatin as a second cytotoxic agent with 5-fluorouracil. In the ACT II study that was given at a dose of 60 milligrams per meter squared on days 1 and 29 along with the 5-FU at the regimen I talked about previously. There is other lower level of evidence data suggesting that even the 5-FU and cisplatin can be given on a weekly schedule and that that can be safe. Actually, at my institution at MD Anderson, that is our standard practice pattern as well. There's also the option when we're thinking about giving pelvic radiation for patients with lower GI cancers, many oncologists in the treatment of localized rectal adenocarcinoma are accustomed to using capecitabine as a chemosensitizer in patients with localized rectal cancer. If I'm giving chemoradiation for a patient with localized anal cancer, can I substitute the intravenous 5-FU with oral capecitabine? And although the evidence is not as strong in terms of available data with regards to randomized controlled trials, there certainly is data that suggests that capecitabine may be an acceptable alternative in lieu of intravenous 5-fluorouracil that would be given at a dose of 825 milligrams per meter squared on days of radiation. But certainly, I think that that's a feasible approach as well and maybe even associated with less hematologic toxicity than intravenous 5-FU would be. Brittany Harvey: Great. It's important to understand all the options that are out there for patients with early-stage anal squamous cell carcinoma. So in addition to those chemoradiation recommendations, what is recommended from the expert panel regarding induction chemotherapy or ongoing adjuvant chemotherapy for this patient population? Dr. Van Morris: When we think about treating patients with lower GI cancers with curative intent therapies, when we think about the more common rectal adenocarcinoma, oncologists may be used to giving chemoradiation followed by subsequent cytotoxic chemotherapy. But actually when you look at the data for anal cancer, really there's not any data that strongly supports the use of either induction chemotherapy prior to chemoradiation or adjuvant post-chemoradiation chemotherapy. The RTOG 98-11 study was a trial which evaluated the role of induction 5-fluorouracil prior to chemoradiation and did not show any survival benefit or improved outcomes with the use of induction chemotherapy in a randomized control trial setting. The ACT II trial, which I referenced earlier, was a 2 x 2 design where patients were either randomized to concurrent chemoradiation with 5-FU mitomycin C or concurrent chemoradiation with 5-FU cisplatin. But then there was a second randomization after chemoradiation where half of the study participants received adjuvant cisplatin 5-fluorouracil after completion of their chemo radiation, or the other half were randomized to the standard of care, which of course would be observation. And what that trial showed was that there was no added benefit with the addition of post-chemoradiation cytotoxic chemotherapy. So we look at these data and say that in general, for the general population of patients with localized stages I to III anal cancer, there really is no supporting data suggesting benefit of either induction chemotherapy or adjuvant chemotherapy. And to that end, really it's concurrent chemoradiation remains the standard of care at this time for patients with a new diagnosis of localized anal cancer. Brittany Harvey: Absolutely. It's just as important to know what is not recommended as it is to know what is recommended for these patients. And so I thank you for explaining the evidence behind that decision from the panel as well. So then, are there any other considerations for special populations that oncologists should consider? Dr. Van Morris: I think so. I think that anal cancer is a disease where we don't see that many patients being diagnosed earlier at a younger age, especially in relation to the alarming trend of early onset colorectal cancer that we're currently seeing right now. So there may be patients who come with a new diagnosis of localized anal cancer who are an octogenarian at an advanced age or may have other significant medical comorbidities. And if that is the case, we get called about this quite frequently from outside institutions. I have an 85 year old who is coming to my clinic with this diagnosis. I don't feel comfortable giving this patient doublet cytotoxics, what options do I have? Especially given other organ dysfunction that may precede this diagnosis. And I think that in that case, there are times when it's okay safely to drop the mitomycin C and opt for single agent 5-fluorouracil as a single cytotoxic agent. So I think that that would be something that we've certainly incorporated into our practice at our institution. There's also an association between various autoimmune disorders, patients on immunosuppression, even persons living with HIV being at higher risk for this virally associated cancer. So I think that, again, if the patient is coming with baseline immunosuppression for these reasons prior to treatment, certainly kind of being in tune to the potential for hematologic toxicity. And watching these patients very closely as they're getting chemoradiation remains really important. Brittany Harvey: Definitely. So, you've just discussed some of those comorbidities and patient characteristics that are important for clinicians to consider when deciding which regimens to offer. So in addition to those, in your view, what is the importance of this guideline and how will it impact clinical practice for clinicians who are reading this guideline. Dr. Van Morris: Chemoradiation remains a very effective option and most patients will be cured with this diagnosis and with this treatment. So it's important to make sure that these patients are able to safely get through their treatment, minimizing treatment delays due to toxicities which may come about because of the treatment, and really help to carry them over the finish line so that they have the best likelihood for achieving cure. So we really hope that these data will provide oncologists with a readily available summary of the existing data that they can refer to and continue to help as many patients as possible achieve and experience a cure. Brittany Harvey: Absolutely. So then to build on that, it's great to have this first guideline from ASCO on anal squamous cell carcinoma. But how will these new recommendations affect patients with stage I to III anal cancer? Dr. Van Morris: I certainly hope it will allow patients and oncologists to know what their options are. It certainly is not a one size fits all treatment approach with regards to the options which are available. Depending on the patient, depending on the various medical conditions that may accompany them, these treatments may need to be tailored to most safely get them through their treatment. Brittany Harvey: I appreciate you describing the importance of this guideline for both clinicians and patients. So what other outstanding questions and future research do you anticipate seeing in this field? Dr. Van Morris: It's a really good question and I think that there is a lot coming on the horizon. Even though the standard treatment has really not changed over the last half century, I think it still remains true that not all patients will achieve cure with a chemoradiation treatment. So a recent trial has completed enrollment in the United States, this is the EA2165 trial led by one of our committee members, Dr. Rajdev and Dr. Eng as well, that's looking at the use of nivolumab anti PD-1 immunotherapy after completion of concurrent chemo adiation. So in that trial, patients were randomized to concurrent chemoradiation followed by either observation or six months of adjuvant anti PD-1 therapy. We're really awaiting the results of that. Hopefully if we see an improvement with the addition of nivolumab following concurrent chemoradiation, our hope would be that more patients would be able to achieve a cure. So we're certainly looking forward to the outcomes of that EA2165 study. And then I think one question that we often get from our patients in the clinics is, “What is the role of circulating tumor DNA in the management of my disease?” And really, to date there have been some series which have shown that we can assess patients or circulating tumor DNA after completion of their concurrent chemo radiation that may need to start about three months after to give time for the radiation to wear off and most accurately prognosticate that. But I think that this will be a powerful tool moving forward, hopefully, not only in the surveillance to identify patients who may be at high risk for recurrence, but ultimately to translate that into next generation clinical trials which would treat patients at higher risk for recurrence by virtue of a detectable circulating tumor DNA result. In doing so, hopefully cure even more patients with this diagnosis. Brittany Harvey: Yes, we'll look forward to these developments and hope to add more options for potential treatment and surveillance for patients with anal cancer. So, I want to thank you so much for your work to develop these guidelines and share these recommendations with us and everything that the expert panel did to put this guideline together. Thank you for your time today, Dr. Morris. Dr. Van Morris: Thank you. And thank you to ASCO for helping to keep this information out there and ready for oncologists for this rare cancer. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.    

BUFFALO, NY - November 12, 2024 – A new #review was #published in Oncotarget's Volume 15 on November 7, 2024, entitled “Understanding the interplay between extracellular matrix topology and tumor-immune interactions: Challenges and opportunities.” This comprehensive review by researchers Yijia Fan, Alvis Chiu, Feng Zhao, and Jason T. George from Texas A&M University, Rice University, and MD Anderson Cancer Center sheds light on how the structural properties of the extracellular matrix (ECM) within tumors impact immune cell behavior and influence the effectiveness of cancer immunotherapies. The ECM, a network of proteins surrounding cells, often transforms in cancer, becoming denser and more aligned. These changes create physical barriers that can prevent immune cells, especially T cells, from effectively accessing and attacking tumors, thereby limiting the success of immunotherapies. The team emphasizes the role of specific ECM configurations, known as Tumor-Associated Collagen Signatures (TACS), in cancer progression and immune evasion. TACS1 and TACS2 patterns create "immune deserts" around tumors, limiting immune cell movement and preventing T cells from recognizing and attacking cancer cells, which is essential for successful immunotherapy. In advanced stages, TACS3 aligns ECM fibers in ways that both promote tumor spread and create additional barriers, further obstructing immune cell access to the tumor. These insights lead the way for ECM-targeted therapies designed to modify these barriers, potentially transforming “cold” (immune-non-responsive) tumors into “hot” (immune-responsive) ones, thereby improving immune cell infiltration and enhancing treatment outcomes. “Understanding the complex interplay is relevant for developing more accurate model of tumor evasion and the identification of corresponding therapeutic intervention.” The review highlights advanced computational models that simulate interactions between the ECM, immune cells, and tumors, offering valuable insights for developing ECM-targeted therapies. These models illustrate how modifying ECM properties could enhance immune cell migration and function, potentially overcoming immune resistance and expanding the effectiveness of immunotherapies. The authors also suggest that targeting ECM structure could significantly enhance the effectiveness of immunotherapy, especially for cancers like breast, pancreatic, and ovarian, which often feature dense ECM regions. By reshaping the ECM, such treatments could enable immune cells to access previously unreachable tumor areas, presenting a promising strategy to combat tumors that are resistant to standard therapies. In conclusion, the review underscores the need for continued research into ECM-focused strategies, which could support more integrated approaches to cancer treatment. By targeting the ECM's physical barriers and immune evasion mechanisms, these strategies hold promise for improving outcomes in difficult-to-treat cancers. DOI - https://doi.org/10.18632/oncotarget.28666 Correspondence to - Jason T. George - jason.george@tamu.edu Video short - https://www.youtube.com/watch?v=7Wm-SMLJadk Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28666 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Drs. Anne Knisely and Nitecki Wilke to discuss Racial and Sociodemographic Disparities with Novel Therapeutics. Dr. Knisely is a 3rd year gynecologic oncology fellow at MD Anderson Cancer Center. She is originally from the New York City area and completed her residency training in Ob/Gyn at Columbia University in 2022 where Dr. Jason Wright served as her primary research mentor. Her current research focuses on early phase clinical trials, minimal residual disease in ovarian cancer, and sociodemographic factors that affect oncologic treatment and outcomes. She is a current SGO/GOG-F BRIDGES Research Scholar. In her free time, she mostly chases around her two toddlers, Zoe (3.5) and Isaiah (2). Dr. Nitecki Wilke is a gynecologic oncologist and assistant professor at the department of gynecologic oncology and reproductive medicine at the University of Texas MD Anderson Cancer Center.   Highlights: Of the 6242 patients who met inclusion criteria and were included in the final cohort, 4.4% received a PARP inhibitor, 34% received bevacizumab, and 6% received both.  On multivariable analysis, non-Hispanic Black patients were 23% less likely than non-Hispanic white patients to receive either targeted therapy Most patients in the study were treated in the recurrent setting; we suspect that the potential barriers to guideline-concordant prescription of these therapeutics would persist in the upfront treatment setting, but future studies are required to validate this. A key area of focus to reduce disparities in access to targeted therapies should be ensuring adequate reimbursement for genetic/ biomarker testing as well as brainstorming creative solutions to expand access to genetic counseling, including the use of mainstreaming. Use of the SEER-Medicare database specifically reduces external validity of this study, but the results are nonetheless hypothesis generating and should spark conversation regarding potential inequitable receipt of PARP inhibitors and bevacizumab in advanced ovarian cancer

Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of gynecologic oncology, focusing specifically on endometrial cancer. Hosted by Drs. Rohit and Rahul Gosain, this episode features Dr. Shannon Westin, a Professor of Gynecology, Oncology, and Reproductive Medicine at the MD Anderson Cancer Center. In this episode, we explored: •⁠  ⁠The different histologies of endometrial cancer, including endometrioid, serous, clear cell, and undifferentiated types. •⁠  ⁠The evolving landscape of molecular classification and its impact on treatment decisions. •⁠  ⁠The current treatment paradigms for early-stage and advanced endometrial cancer, including the role of surgery, chemotherapy, and immunotherapy. •⁠  ⁠The significance of NGS (Next-Generation Sequencing) testing in identifying actionable mutations, such as MSI-high tumors and HER2-positive cancers. •⁠  ⁠The latest advancements in adjuvant therapies and the potential of combining chemotherapy with immunotherapy. Whether you're a healthcare professional or simply interested in the latest developments in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't forget to like, subscribe, and check out our other discussions focusing on ovarian cancer and more! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Join us for a conversation with Dr. Raghu Kalluri, a leading figure in cancer biology, who serves as the Chair of the Department of Cancer Biology at MD Anderson Cancer Center. With over 300 publications, multiple successful biotech ventures, and groundbreaking work in exosome research, Dr. Kalluri discusses the intricate relationship between science, medicine, and industry, his career path from researcher to entrepreneur, and his exciting vision for using innovation to transform cancer care.

In this episode, we welcome Shalini Yadav, a 2024 Executive MBA graduate and visionary leader in the field of synthetic biology. With over 22 years of research experience, including a decade in leadership, Shalini has a deep expertise in synthetic biology, immuno-oncology, and therapeutics. She now serves as the Executive Director of Rice's Synthetic Biology Institute, where she spearheads cutting-edge research, fosters interdisciplinary collaboration, and drives the institute's mission to unlock synthetic biology's transformative potential.Host Maya Pomroy '22 speaks with Shalini about her inspiring journey from growing up in Allahabad, India, to leading translational cancer research at MD Anderson Cancer Center in Houston. Shalini reflects on how her early experiences with infectious diseases and her education, from New Delhi to Stony Brook University, shaped her passion for synthetic biology. She also shares her thoughts on the field's potential to revolutionize science and the critical role of integrating business strategy into scientific innovation.Episode Guide:02:39 Early Life and Education04:13 Challenges and Adventures in the US07:08 Groundbreaking Research and Discoveries10:00 Transition to Translational Research14:23 Journey to MD Anderson and Houston17:17 Why Pursue an MBA Now?27:16 Synthetic Biology: The Next Scientific Revolution37:48 Future Aspirations and ConclusionOwl Have You Know is a production of Rice Business and is produced by University FM.Episode Quotes:How a serendipitous opportunity brought Shalini to Houston14:09: [Maya Pomroy] So what brought you to Houston? Was it MD Anderson that brought you to Houston?14:35: [Shalini Yadav] When I got an opportunity, again grateful to the PCF Young Investigator Award that I got, this network of people that I met, and through that, I was able to connect with Dr. Allison, and it, again, serendipitously, happened that he, looking at my expertise and things that I had done, said, “Would you like to do this work, which is a lot of scientific management and administrative?” [15:06] I thought, okay, as long as I found it interesting and exciting, because, again, I was handling multiple stakeholders and trying to work with multiple pharmaceutical companies, different departments, different kinds of experts, working together with all of them to handle a scientific problem, which will actually help to learn something new. So that was very satisfying to do that.How an MBA gave Shalini a new perspective on impact32:42: I would like to say that scientists in general are passionate about what they do. It's the leap that you have to take that overcome, and your perspective changes after MBA. I never had this perspective. The way I understand things now are completely different than I would have done two years back. 33:18: So if community matters to you and if you're bothered by things around you, which you want to change and you think with this you cannot. I think taking that leap where you will learn things, which I think basically as a scientist, our training as graduate students, or even medical studies, we are taught to be very focused. So having to come out of that shell and embrace this bigger picture and having the strength to think about what impact I can have because if you understand both sides of it, what you can think of achieving, you won't get it if you are just on one side of things. The effect of bridging the gap between clinical and translational research and basic research11:35: When you bring diverse expertise together, the solutions that come out have way more value and are more impactful than what you can achieve alone. So bridging this gap was not something that I was looking for, but I serendipitously got into a position where I just did what was needed, which gave me a very different perspective of what scientific research can achieve in terms of, if you understand the problems which people are actually facing, then your solutions can be tailored, or you can design proposals to address those problems.Show Links: TranscriptGuest Profiles:Shalini Yadav | LinkedInRice Synthetic Biology Institute MD Anderson Cancer CenterYoung Investigator Awards | Prostate Cancer FoundationWorld Health Organization Catch our previous episode with Jillian Lebovitz Fink: "A Former Fourth-Grade Teacher Is Working to Ease Your Migraines." Listen now: https://business.rice.edu/owlhaveyouknow/season-3-episode-16

This episode of ASTCT Talks dives into outpatient CAR T therapy, exploring logistics, challenges, and success strategies. Host Dr. Zahra Mahmoudjafari leads a panel of experts to share insights from their innovative programs. The panel features Robb Richards, Administrative Director of Cell Therapy and Transplant at Penn Medicine; Dr. Katie Gatwood, Clinical Pharmacy Specialist at Vanderbilt University Medical Center; and Dr. Taha Al-Juhaishi, Associate Director at the University of Oklahoma's Transplant and Cell Therapy Program. Topics include outpatient program structures, toxicity management, and the evolving role of cell therapies beyond hematologic malignancies. About the Host:Dr. Zahra Mahmoudjafari is a board-certified oncology pharmacist and Clinical Pharmacy Manager in Hematologic Malignancies at the University of Kansas Cancer Center. She earned her PharmD and MBA from UMKC and focuses on clinical and operational management of cell and gene therapies. Dr. Mahmoudjafari is active in HOPA, ATOPP, and ASTCT and was honored with ASTCT's Pharmacy SIG Lifetime Achievement Award and ASCO's 40 Under 40 in Cancer Award. Meet the Panel: Robb Richards has over 20 years of oncology experience, with roles spanning private practice, IT, and leadership in healthcare systems. At Penn Medicine, he oversees CAR T therapy operations, expanding services into community hospitals. He holds degrees from Drexel University and St. Joseph's University. Dr. Katie Gatwood is a Board-Certified Oncology Pharmacist at Vanderbilt University Medical Center, where she leads the PGY2 Oncology Residency Program and chairs the ASTCT Pharmacy SIG. Her expertise spans CAR T therapy, transplant conditioning, and GVHD therapies. Dr. Gatwood is an award-winning practitioner and has authored several publications on oncology pharmacy practice. Dr. Taha Al-Juhaishi is an attending physician and clinical investigator at OU Stephenson Cancer Center, Oklahoma's only NCI-designated center. He serves as associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy program and leads several clinical trials. Dr. Al-Juhaishi trained at Weill Cornell Medicine, VCU, and MD Anderson Cancer Center. Listeners will gain valuable insights into the complexities of managing outpatient CAR T therapy and strategies to enhance patient care.

On this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

In this informative episode of Bladder Cancer Matters, host Rick Bangs welcomes back Dr. Ashish Kamat, an expert in urology and bladder cancer research from MD Anderson Cancer Center. They dive into the latest updates on BCG (Bacillus Calmette-Guérin) and its crucial role in treating non-muscle invasive bladder cancer. Dr. Kamat provides an insightful overview of BCG's effectiveness, the current shortage, and emerging alternatives. He explains the factors behind the supply issues and how treatments such as reduced dosages and novel combinations like gemcitabine and docetaxel are helping to bridge the gap. Listeners will also hear about promising new therapies on the horizon, including gene therapy with Adstiladrin, Pembrolizumab, and ANKTIVA's combination with BCG. Dr. Kamat sheds light on how these advancements could change the landscape of bladder cancer treatment while emphasizing the importance of tailored care and shared decision-making for each patient. This episode is a must-listen for those affected by bladder cancer and anyone interested in the latest medical developments in this field.

In this episode, we review key components of the landmark MAGIC and FLOT-4 trials that investigated perioperative chemotherapy in the treatment of locally advanced gastric cancer.  We discuss limitations of both trials and the evolving clinical landscape of gastric cancer treatment. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Associate Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist/HPB surgeon at Brooke Army Medical Center. - Daniel Nelson, DO, FACS (@usarmydoc24) is a Surgical Oncologist/HPB surgeon at Kaiser Permanente Los Angeles Medical Center. - Connor Chick, MD (@connor_chick) is a Surgical Oncology Senior Fellow at Ohio State. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology Junior Fellow at MD Anderson Cancer Center. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center.  Learning Objectives:  1.     Understand background, methodology, results, and interpretation of the MAGIC trial. 2.     Understand background, methodology, results, and interpretation of the FLOT trial. 3.     Be able to discuss the evolution of chemotherapeutic regimens in the treatment of locally advanced gastric cancer and rationale for their use. 4.     Be able to describe key limitations for the above regimens. 5.     Discuss the the evolving clinical landscape for chemotherapy in gastroesophageal junction tumors. Links to Papers Referenced in this Episode: Journal Articles: Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., ... & Chua, Y. J. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11-20. https://pubmed.ncbi.nlm.nih.gov/16822992/ Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., ... & Hofheinz, R. D. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet, 393(10184), 1948-1957. https://pubmed.ncbi.nlm.nih.gov/30982686/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

SymPhysis Medical, the Galway MedTech company seeking to address the distressing condition of fluid in the chest in cancer patients, today announces that it has received €2.2M in funding as it prepares for regulatory clearance in the US. The funding consists of follow-on investments from Irrus Investments, the MedTech Syndicate and Boole Investments along with capital from Enterprise Ireland and a new private investor SymPhysis Medical has been working with global leaders in cancer care to develop releaze, a device for cancer patients who are suffering from fluid in the chest. The condition impacts 50% of end-of-life cancer patients and can cause pain and shortness of breath1. It requires frequent hospital visits for treatment. SymPhysis Medical's founders, Tim Jones and Dr Michelle Tierney, identified the unmet clinical need for better treatment of the condition as part of the BioInnovate programme run by University of Galway. Their device offers a less invasive alternative to current treatments and can be managed from a patient's home, giving patients the freedom and time to pursue the activities they enjoy and to spend time with loved ones. The latest funding for SymPhysis Medical - which follows €1.5M announced in December 2023 - will help the company to launch in the US and reach its first patients. In total, SymPhysis Medical aims to raise €6.5M in 2024 to pursue these activities. releaze is being manufactured in Letterkenny, Co. Donegal, by Phillips Medisize. Key to its launch in the US will be FDA (Food and Drug Administration) clearance, which SymPhysis Medical aims to receive at the end of 2025. In advance of this, the company seeks to carry out the necessary pre-clinical studies required by the FDA for the clearance of medical devices. Additionally, SymPhysis Medical aims to continue carrying out usability studies with the UK's National Innovation Centre Ageing (NICA) and Mayo Clinic. The goal of these is to provide vital evidence that the device functions exactly as it is marketed. Approval in the US would mean that SymPhysis Medical could reach its first 10 to 20 patients using the funding it has received. The target will be to treat those under the care of MD Anderson Cancer Center in Houston, Texas - the largest of its kind in the world - and Mayo Clinic in Rochester, Minnesota. SymPhysis Medical has been working alongside clinicians in both of these institutions for the last five and seven years respectively. If granted FDA clearance, SymPhysis Medical's next goal will be to seek the CE mark, which would enable it to market its device in Europe. Tim Jones, CEO, SymPhysis Medical, said: "At SymPhysis Medical, our focus has always been on the patient and enhancing their quality of life as they receive palliative care. Despite the seriousness of their condition, these patients can still lead active lives; we have met patients who are still jogging, hiking and swimming. Regardless of how active their condition allows them to be, cancer patients receiving palliative care all have one thing in common: they are determined to ensure that the time they have remaining is enriched and fulfilling - and that requires as little time in hospital as possible. "That has been the driving force behind SymPhysis Medical and six years on from our foundation, we are excited to be getting to the point when we can finally see our device benefiting patients. This would not have been possible without the support of our investors, who have seen that this is an unmet clinical need with global market potential. We have also been able to demonstrate to them that this is a device with the support of global leaders in cancer care, so there is no question about the appetite for it - it is all about getting it to our first patients as soon as possible." Dr Horiana Grosu, Director of Pleural Service in MD Anderson, said: "The insertion process for this device is straightforward and the drainage system is user-friendly, offering patients great...

The Rush Cell Therapy Lab provides stem cell transplants, bone marrow transplants and other advanced cell therapy treatments for patients with leukemia, lymphoma, multiple myeloma, and other hematological malignancies. In addition, the lab will soon function as a contracted manufacturing facility partner for the production and quality control and release of cell and gene therapies, representing a significant leap in decentralized hospital based cellular therapeutic manufacturing. Mahzad Akbarpour, PhD, is the Director of the Rush Cell Therapy Lab at RUSH MD Anderson Cancer Center and is also an Assistant Professor of Internal Medicine in the Division of Hematology, Oncology, and Cell Therapy. “When CAR-T cells first came on the market a few years ago, Rush was one of the first centers in the nation to provide this therapy to its patients. We've also been involved in several clinical trials to advance care and we'll soon be able to manufacture our own cells on-site.”

Dr. Fumiko Chino and Dr. Raymond Osarogiagbon share highlights from the 2024 ASCO Quality Care Symposium, including patient perspectives and compelling research on topics like equity, supportive care, survivorship, and technology and innovation. TRANSCRIPT Dr. Fumiko Chino: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Fumiko Chino, an assistant professor in radiation oncology at the MD Anderson Cancer Center. On today's episode, we'll be highlighting key research and compelling perspectives that were featured at the 2024 ASCO Quality Care Symposium. I was delighted to serve as the chair-elect of this meeting's program committee, and I'm overjoyed to welcome its chair, Dr. Raymond Osarogiagbon, to the podcast today. He is the chief scientist at the Baptist Memorial Health Care Corporation and the director of the Multidisciplinary Thoracic Oncology Program at the Baptist Cancer Center in Memphis, Tennessee. Our full disclosures are available in the transcript of this episode, and we've already agreed to go by our first names for this podcast today. Ray, it's so great to speak with you today. Dr. Raymond Osarogiagbon: Thank you, Dr. Chino, and thank you for letting me call you by your first name. Dr. Fumiko Chino: I think both of our names are complicated enough and so I appreciate the level of familiarity that we've had with each other during the planning process for this fantastic meeting. Now, the Quality Care Symposium featured some really compelling research on very timely topics that address a wide range of issues in cancer care, including quality, safety, equity, supportive care, survivorship, and technology and innovation. Wow, what a lot to cover. Ray, do you mind sharing with me some of the key sessions that really stood out for you? Dr. Raymond Osarogiagbon: Yes, Fumiko, this was such a great conference. Our tagline this year was ‘Driving Solutions, Implementing Change.' We had more than 700 attendees in person and virtually. The Symposium featured many fantastic speakers, oral abstracts, posters, and we had networking opportunities for junior colleagues to interact with leaders in the space. We had conversations that will surely inspire future collaborations to improve quality cancer care. We had patients, advocates. I was inspired by the patient perspectives that were presented, learned a lot. And I really felt like this enhanced our understanding of some of the key issues that we see in our clinics. I was honored to be able to introduce my dear friend, Dr. Ethan Basch from the University of North Carolina, Chapel Hill, who received the Joseph Simone Quality Care Award this year. Dr. Basch gave a talk titled, “On the Verge of a Golden Age in Quality Cancer Care.” In his talk, which received a standing ovation, Dr. Basch tracked his personal development from fellowship training at Memorial Sloan Kettering through a junior faculty position at the same institution under the mentorship of Dr. Deborah Schrag, and ultimately to his current position as chair of oncology at the University of North Carolina and as physician-in-chief at the North Carolina Cancer Hospital. In parallel, with the evolution of the patient-reported outcomes movement that he has been right at the heart of, and also the evolution of cancer care delivery research into its current position of prominence in oncology. That was a spectacular talk, and it rightly received a standing ovation. We also had presentations and panel discussions that addressed patient navigation and cancer care moving from theory to practice, which provided wonderful, diverse perspectives on the evidence-based approaches to patient navigation and cancer care. And a wonderful session on the complexities of the pharmaceutical supply chain and what everyone in oncology should know that looks at the current challenges in the pharmaceutical supply chain. Leveraging technology to support patient-centered multidisciplinary care [was also covered], and we talked about health-related social needs and the impact of diversity, equity and inclusion on the oncology workforce. Patient care perspectives were just incredible. So, Fumiko, as an equity researcher, I really want to hear your key takeaways from some of these discussions. Dr. Fumiko Chino: I have to say, I was so impressed with not just the science that was presented, but also the passion from some of our educational speakers who are really speaking from their expertise and their commitment to try to continue to advance equity in the field of cancer care. And as someone who is still a relatively junior researcher, I feel that the work that I've done over the last decade has really been built on the shoulders of these giants. Just harkening back to you had mentioned that Dr. Basch essentially gave an overview of his career and as a young health services researcher, I've been really impressed about how generous the leaders in the field have been with their time not only to discuss their research at this conference, but also to talk to trainees and fellows and junior researchers and really share the wealth of their knowledge. In terms of equity research presented at the conference though, I was really struck by the overview we were able to provide about the best care to provide to LGBTQ patients. Dr. Mandy Pratt-Chapman actually gave a really lovely overview that was always centered in the patient. It really taught me a lot about what the best practice is to not just collect SOGI data to improve research, but also that there's billing codes that can actually help decrease the chance that a patient may be misbilled based on anatomical misunderstanding of their gender identity. I was very impressed about the capacity for some of our researchers to really think outside of the classic box for DEI research. So not just race as a social construct, ethnicity, but also health literacy barriers. There was a fantastic analysis looking at a randomized control trial (Abstract 385) that actually showed that patients with low health literacy actually got the most benefit from a digital intervention that involved text reminders to increase adherence. And the flip side of health literacy is that we know that the specific interventions that we do really need to be explicitly designed for the populations that they will be implemented on. Dr. LoConte actually had the results from her intervention looking at a radon mitigation indigenous communities (Abstract 44). And I was so impressed about her commitment to the process of listening to the communities and what their needs were, what their concerns were, and then implementing this community led intervention that helped mitigate the radon risk from many households where the actual radon levels were surprisingly high, beyond what they were that what they were anticipating. And so, it's all of these manifestations of how do we actually improve research, how do we advance the field and further the conversation in an era when it seems like DEI is really under attack. Well, I know you've long been an advocate for equity for lung cancer. And I know that you were actually involved in one of the amazing abstracts being presented that was essentially a decade- long QI (quality improvement) project to try to improve standards of care for lung cancer in a high-risk community in the Mississippi Delta (Abstract 278). And it actually showed over time that this surgical pathology intervention actually was able to improve overall survival for lung cancer. I know that this is part of the work that you've been doing for years. Can you talk a little bit about what was presented within the Symposium specifically for lung cancer, including your study? Dr. Raymond Osarogiagbon: Yes, Fumiko. The member of my team, Olawale Akinbobola, who has an MPH that he actually acquired within my research team I'm proud to say, had the wonderful opportunity to present this work on implementing surgical quality improvement, and in parallel, pathology quality improvement in a well-defined population involving 14 hospitals in seven health care systems across five contiguous hospital referral regions in Mississippi, Arkansas, and Tennessee, at the heart of the Mississippi Delta region. So Olawale showed that over the course of four consecutive 5-year time spans, the quality of surgery has improved from a time when using current objective benchmarks of surgical quality, anywhere from 0-5% of resections met these current standards. So basically, applying today's standards, but retrospectively, to where, as the interventions took hold, we now got to a point where about 67% of the sections in this population now attain surgical quality. And we saw in sequential lockstep with that, that the hazard of death among these patients has significantly decreased. All the way, I think using the first 5 years as the reference, the hazard reduced about 64%. Really amazing to see. But you know, there were other fascinating abstracts. There was a randomized controlled trial, Abstract 185, that demonstrated that olanzapine therapy was actually way more effective than prochlorperazine for patients with intractable chemotherapy-induced nausea and vomiting. I found that very compelling abstract. And then there was Elyse Richelle Parks who reported on the effectiveness of a virtual sustained tobacco treatment, Abstract 376 [a clinical trial conducted by ECOG-ACRIN within the NCI Community Oncology Research Program]. This tobacco control intervention is remotely administered using technology that was presented in today's session on leveraging technology to enhance multidisciplinary care delivery.  That too was amazing to behold. Dr. Fumiko Chino: I've been so impressed within my, at least my interactions with the Quality Care Symposium for the last several years about how this meeting really creates the perfect space for this type of science, which can be frankly underappreciated at other meetings. You know, something like a QI project, a quality improvement project leading to an overall survival benefit or a trial like you mentioned, the randomized control trial for olanzapine, which specifically had a quality-of-life endpoint, meaning that patient quality-of-life was a compelling justification for optimal nausea control. These things are really underappreciated sometimes at the larger scientific meetings, and the ASCO Quality Care Symposium is really where these types of studies and this type of research really shines; it's very patient-centered. You mentioned the patient voice being a really integral part, and I certainly agree with that. The entire meeting started with a session featuring a phenomenal patient advocate, Jamil Rivers, who was diagnosed with de novo stage 4 metastatic breast cancer. And her experience with her primary treatment really highlighted some of the care gaps that Black women experience in their journey with breast cancer. And it really charged her to actually create a patient navigation organization to help Black women with breast cancer get more evidence-based care to make sure that they were actually asking the questions that needed to be asked, getting the resources that they qualified for, and making sure they were getting evidence-based care. Now shifting gears a little bit, in oncology and across medicine, there's actually been some major challenges with drug shortages. I'd like to ask you about the session that was featured to inform oncologists about what we need to know about navigating the complexities of the pharmaceutical supply chain. Do you mind sharing highlights from that discussion, Ray? Dr. Raymond Osarogiagbon: I will, Fumiko, but before I do that, I have to follow up on what you said about Jamil Rivers, the breast cancer survivor and advocate who leads the Chrysalis Initiative. She made the statement of the meeting [in my opinion] when she said, “A hospital encounter for a Black woman is like a Black man being pulled over by the police.” Wow. I mean, that's a direct quote. It suddenly helped me understand my wife's many years-long anxiety whenever she has to deal with encounters with clinicians and health care systems. But about that wonderful session on the challenges with the pharmaceutical supply chain. For me, there were two key highlights. One was Dr. Deborah Patt's discussion on the growing influence of pharmacy benefit managers, PBMs, on the cost and delivery of cancer care. And then there is Jason Weston's discussion of how U.S. generic oncology drug manufacturing has moved almost entirely out of the U.S. with this incredible unrealistic price focus, almost so focused on price competition, almost totally ignoring quality and safety. And paradoxically, that fierce competition has inhibited competition, right? So as the margins have shrunk and all these generic drug manufacturers have moved overseas with little oversight, the supply chain gets disrupted because these companies are not able to invest in processes, in their manufacturing facilities and so on. So, when something goes wrong, all of us become vulnerable. And the other striking thing I learned from Jason was this problem is not new. It is not new. It's been with us for decades. And without comprehensive solutions, unfortunately, it's not going to go away. So, these are some of the examples of things that I would really love the podcast audience to go and check out for themselves. Dr. Fumiko Chino: I will just highlight one additional aspect of that session, which was actually the oral abstract (Abstract 1) that was embedded into the session that was specifically about how when during the cisplatin shortage of last year, when that drug was out of stock, which is honestly a very widely available, typically cheap medication, Dr. Jody Garey actually presented on the fact that the things that were substituted were actually far more expensive, and that actually led to not just people not getting the standard of care due to the drug shortages, but also increased costs. So, the bizarre side effect of the race to the bottom in terms of price competition is the fact that during these shortage periods, there's actually a sharp increase in the overall cost, not just to the administration, but also in terms of payer costs and patient cost sharing. So, it is sort of a lose-lose situation. And that was really highlighted to me by that abstract. And I'm so grateful for the research that really puts these experiences that we see in our clinic, things like drug shortages, in a larger perspective of how things like health policy and reimbursement and some of the nitty-gritty that goes on beyond the scenes in terms of oncology practice really is ending up impacting patient care. Now Ray, is there anything else you'd like to highlight before we wrap up the podcast? Dr. Raymond Osarogiagbon: One I maybe should highlight was the discussion about DEI, which is obviously a contentious topic. And we had Dr. Tawana Thomas Johnson with the American Cancer Society tell us how DEI has evolved from something that everybody seemed like they were eager to support and champion in 2020 to a kind of backlash...how we moved from $5 billion in pledges by corporations to support DEI initiatives in 2020 after the George Floyd murder to now where everybody is wanting to roll things back. And yet in the face of this, wanting to roll things back, wanting to respond to the inevitable backlash, there is this commitment still that some companies have had to DEI and workforce development ideas, so nevertheless, ongoing support. For me, that was a bright spot. Dr. Fumiko Chino: I have to say, as someone who started going to the ASCO Quality Care Symposium as a trainee, I've been really encouraged myself in terms of bright spots for this meeting about the engagement from trainees, from medical students to residents and fellows to early faculty. We even had someone who had just graduated high school ask us one of the questions in a session. And that really highlighted for me that this meeting is a very young meeting. It really is the next generation of health services researchers. And that has always been one of the joys about some of the discussions because I feel like the science presented, the education presented is sparking new collaborations, new research paradigms, new mission driven research for another generation. And it's been just simply phenomenal. Dr. Raymond Osarogiagbon: Yeah, the networking opportunities. Wow. It was such a joy to behold people getting together, breaking off in small clusters, interacting with each other, strangers meeting and hitting it off. I mean, just what a wonderful meeting this is. Dr. Fumiko Chino: Yeah, I have to highlight that. Certainly, at my first ASCO Quality meeting at this point, I think eight years ago, I went to one of those Meet the Expert luncheons, had a great conversation with a phenomenal researcher who I still obviously very much admire. And I was sitting at a table at a Meet the Expert luncheon today. And I just felt so invigorated by some of the conversations that I had with the next generation of researchers about how to define their lane, their passion, and how to continue to advance the field. Thank you, Ray, for sharing your key takeaways from the 2024 ASCO Quality Care Symposium and for leading a truly robust program this year. Dr. Raymond Osarogiagbon: Thank you, Fumiko. This has been a labor of love as you will find when you take on this responsibility for next year's meeting. This has been my pleasure. Dr. Fumiko Chino: Thank you so much. I'm really excited about the program that we're going to start planning in Chicago next year. Everyone listening can mark their calendars for October in Chicago. I really want to thank our listeners for your time today. You will find the links to the sessions and the abstracts that we discussed in the transcript of this episode. And if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer:    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.    Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: Dr. Fumiko Chino @fumikochino Dr. Raymond Osarogiagbon  @ROsarogiagbon    Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures:  Dr. Fumiko Chino: No relationships to disclose Dr. Raymond Osarogiagbon:   Stock and Other Ownership Interests: Lilly, Pfizer, Gillead  Honoraria: Medscape, Biodesix  Consulting or Advisory Role: AstraZeneca, American Cancer Society, Triptych Health Partners, Genetech/Roche, National Cancer Institute, LUNGevity  Patents, Royalties, Other Intellectual Property: 2 US and 1 China patents for lymph node specimen collection kit and metho of pathologic evaluation   Other Relationship: Oncobox Device, Inc.

Palliative care is an essential component to high-quality care for patients with cancer. How can access to palliative care be expanded? Eduardo Bruera, MD, from MD Anderson Cancer Center speaks with JAMA Editor in Chief Kirsten Bibbins-Domingo about 2 new trials in JAMA that address access to care and what more it will take for executives, insurers, and regulators to support palliative care programs. Related Content: Improving Palliative Care Access for Patients With Cancer Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer

A contract dispute has caused the removal of MD Anderson from BC/BS TX Medicare Advantage networks. This will be a problem for their member patients who relied on Anderson for their treatment. This sad upheaval couldn't happen with Medicare and a Medicare supplement! The Medicare Advantage Minute quotes an article illustrating the areas of the US where millions could lose their MA plans. From the Medicare Wikipedia page we learn about office medication reimbursement. Wellcare is ending MA coverage for their clients in six states. Finally, correspondence from two prospective clients with questions about their unique situations. Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+)   Inspired by: "MEDICARE FOR THE LAZY MAN 2024; Simplest & Easiest Guide Ever!" on Amazon.com. Return to leave a short customer review & help future readers. Official website: https://www.MedicareForTheLazyMan.com.

While we often like to talk about research findings that shows us statistical significance in data and solid numbers we can lean on for treatment approaches… What about the kind of data that ISN'T objectively measured? The kind that shows us what patients or other clinicians experience think, or believe. I'm talking about qualitative research! Is qualitative research viewed as “less reputable” than quantitative research? What kind of valuable information can we pull from patient experiences, opinions, and views? Beatrice Manduchi PhD, MSc, BSc (SLP) is here to talk all about it in today's episode of the Swallow Your Pride podcast! Beatrice is a speech-language pathologist who went from clinician to researcher and is currently working as a postdoc fellow at MD Anderson Cancer Center. Beatrice specializes in dysphagia, particularly in head and neck cancer. Tune into this episode to take a break from numerical data and explore the world of qualitative research and its impact on dysphagia! Link to show notes: https://syppodcast.com/340 TIMESTAMPS: Qualitative Research Interest (00:03:20) Importance of Qualitative Methods (00:05:17) Qualitative Research vs. Quantitative Research (00:06:07) Impact of Qualitative Research on Dysphagia (00:09:37) Patient Perspectives in Research (00:10:51) Integrating Qualitative Research with Clinical Practice (00:12:14) Conducting Qualitative Research (00:15:02) Data Saturation in Qualitative Research (00:17:22) The Role of Frameworks in Qualitative Research (00:20:18) Passion for Patient-Centered Research (00:22:18) Understanding Bias in Interviews (00:23:16) Nuances of Interview Guides (00:24:18) Proactive vs. Reactive Therapies (00:26:11) Patient Comfort with Therapies (00:29:00) Streamlined Processes in Therapy (00:30:22) Patient Education Importance (00:32:52) Setting Diet Goals (00:33:56) Shared Decision-Making Challenges (00:38:01) Surprising Findings from the Study (00:39:17) Next Steps in Research (00:41:22) The post 340 – The Power of Qualitative Research in Speech and Language Pathology – Beatrice Manduchi PhD, MSc, BSc (SLP) appeared first on Swallow Your Pride Podcast.

El cáncer es una de las primeras causas de muerte en el mundo. En 2023 fue responsable del 26 por ciento de los fallecimientos en nuestro país. Por fortuna, se ha avanzado mucho en el diagnóstico y tratamiento, aunque sigue siendo una palabra tabú y un mazazo para pacientes y familiares. Hemos entrevistado a Juan Fueyo, investigador en el MD Anderson Cancer Center de la Universidad de Houston, y autor del libro “Cuando el mundo se detiene. Cáncer, del mito a la esperanza” (Sinequanon). En este programa hemos recuperado el resto de las secciones. Con Humberto Bustince hemos analizado algunos de los riesgos de la IA y la normativa europea que pretende un mayor control. El pasado 1 de julio se cumplió un año del lanzamiento de la misión europea Euclid con el objetivo de desentrañar los misterios de la materia y energía oscuras. Como nos ha contado Montse Villar, nunca antes un telescopio espacial habría logrado imágenes tan nítidas de una zona tan grande y distante del cielo. Con Javier Cacho hemos recordado la operación de rescate que un remolcador ruso llevó a cabo en 1984 para liberar a más de 3.000 ballenas belugas que quedaron atrapadas en los hielos del ártico. Y el doctor Pedro Gargantilla nos ha explicado el origen y significado de la serpiente enrollada en el báculo, símbolo de la medicina. Escuchar audio

Dr. Fletcher is currently a General Surgery Resident at Morehouse School of Medicine, a position he began in June 2024. Before this, he served as an Orthopedic Oncology Research Assistant at MD Anderson Cancer Center from November 2021 to June 2024. Prior to his research role, Dr. Fletcher worked as a Medical Officer in Orthopedics at Spanish Town Hospital from July 2019 to November 2021. His experience spans various roles in surgery and orthopedics across different healthcare settings in the United States and Jamaica.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Kirsten Jorgensen and Alex Melamed to discuss fertility sparing surgery in cervical tumors (

Charisma DeSai, MD, current breast radiology fellow, and Monica Huang, MD, attending breast radiologist and founder of the breast cryoablation program at MD Anderson Cancer Center, discuss a recently published AJR article on breast cryoablation in the context of landmark trials on cryoablation, including patient selection, procedure technique, follow-up, and multispecialty collaboration.  ARTICLE TITLE - Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials: A Multiinstitutional Study

On episode 484 of The Nurse Keith Show nursing and healthcare career podcast, Keith interviews Sonya Kulkarni and Stephanie Wang of The Health Disparities Think Tank (HDTT), an organization born of their mutual dedication to advocacy for policies that contribute to addressing and eradicating the health disparities that plague American society, the healthcare system, and the citizens we are all committed to serving. Stephanie Wang is a student at Harvard College studying Molecular & Cellular Biology and Global Health & Health Policy. She is the Founder and Executive Director of the Health Disparities Think Tank, a multidisciplinary research and policy advocacy group combating health disparities, engaging 40+ students and 20+ mentors in projects addressing maternal mortality, climate change, cancer disparities, etc. Stephanie's research spans applications of stem cell biology in oncology at Boston Children's Hospital and disparities in drug pricing and pharmaceutical innovation at Harvard Medical School, with 10 papers published or under review in scholarly journals. She previously served on the board of Harvard Consulting for Business and the Environment — the largest student-led nonprofit by revenue in the country — where she spearheaded life science initiatives for 200+ members and consulted for three pharmaceutical companies with $200B+ total market cap. On the weekends, she works as a nursing assistant at Massachusetts Eye and Ear and directs Harvard's Alzheimer's Buddies program. Sonya Kulkarni is a student at Harvard College studying Molecular & Cellular Biology and Economics. She is an associate for Harvard Undergraduate Consulting on Business and the Environment and a writer for the Harvard Undergraduate Health Policy Review, and has conducted research in neurodevelopment in pediatric HIV and translational molecular diagnostics at MD Anderson Cancer Center. Sonya is also a National Ambassador for the American Cancer Society and leads policy initiatives for pediatric cancer patients in Congress. Her academic and extracurricular pursuits are fueled by a fervent interest in the intersection between health, policy, and business, particularly in effecting meaningful change in drug pricing and cancer care. Connect with Stephanie Wang, Sonya Kulkarni, and the Health Disparities Think Tank: Health Disparities Think Tank website Health Disparities Think Tank on LinkedIn Stephanie Wang on LinkedIn Sonya Kulkarni on LinkedIn

How do you navigate breast cancer when you know the health care system is stacked against you? And, how, as a health care provider, can you best support marginalized people going through the experience of breast cancer? Let's find out. In this episode, Jasmine Samuel, a TNBC survivor and Black nurse shares how her experience of suboptimal care in Jackson, Miss., encouraged her to actively seek out a better care experience from MD Anderson in Houston, Texas. We'll also hear from Komen Scholar Dr. Mariana Chavez MacGregor, a breast medical oncologist and professor at the Breast Medical Oncology Department of MD Anderson Cancer Center who will discuss how she provides compassionate care and focuses research on improving outcomes for underserved patients.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ann H. Klopp to discuss radiation alone vs chemoradiation in endometrial cancer recurrence. Dr. Ann H. Klopp is a Professor of Radiation Oncology at MD Anderson Cancer Center, the head of the Gynecologic Oncology Section and a physician-scientist specializing in the treatment of gynecologic cancers. Her research focuses on improving outcomes for women with gynecologic cancers by enhancing tumor directed immune response in combination with radiation therapy and using advanced techniques to increase precision of radiation treatment delivery. Highlights: NRG0238 compared chemoradiation to radiation alone for patients with locally recurrent endometrial cancer and found that the addition of chemotherapy did not improve progression-free survival. Radiation therapy is highly effective for treatment for local recurrences of endometrial cancer. The nuances of patients enrolled and treatment delivered are discussed.

Hello Mayhem Mommas!! You won't want to miss this episode where Melanie confesses to why she licked a car that was parked near the beach. Then, Miranda describes all the nauseating in's and out's of the first trimester. Ever wonder why you had to pee so much, or why everything smelled?? Learn how rapidly a fetus grows during these first 90 days of pregnancy. And, to wrap up another zany episode, Mel breaks down the 3 H's that Miranda always got confused... what is the difference between Hernias, Hemorrhoids, and Hemorrhages?? You're about to find out, and you likely won't be able to forget them again after this deep dive! Join us for some laughs, some bestie friendship energy, and maybe a few fun facts along the way!! Spotlight:Catch Global Foundationhttps://www.catch.org CATCH Global Foundation is a 501(c)3 public charity founded in 2014 in partnership and with support from the University of Texas Health Science Center at Houston (UTHealth) and MD Anderson Cancer Center. Our mission is to empower school communities to cultivate Whole Child wellness as a lever for student success and social equity. The Foundation links underserved schools and communities to the resources necessary to create and sustain healthy change for future generations with their health education programs.Sources:Mel-https://my.clevelandclinic.org/health/diseases/15757-herniahttps://my.clevelandclinic.org/health/diseases/15120-hemorrhoidshttps://my.clevelandclinic.org/health/diseases/hemorrhageMiranda-https://my.clevelandclinic.org/health/articles/9699-first-trimesterhttps://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/prenatal-care/art-20045302https://mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/pregnancy/art-20047208 Hosted on Acast. See acast.com/privacy for more information.

Join the Oncology Brothers, Rahul and Rohit Gosain, in this insightful podcast episode as they dive into the world of small cell lung cancer with special guest Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson Cancer Center. Key Points: •⁠  ⁠The Adriatic study's impact on improving survival with Durvalumab in limited-stage disease. •⁠  ⁠Treatment options for extensive-stage disease, including second-line therapies like Lurbinectedin and the recent approval of Tarlatamab. •⁠  ⁠The significance of individualized treatment decisions and ongoing research in small cell lung cancer management. In this episode, Dr. Singhi discusses the management of limited-stage small cell lung cancer, the impact of the recent Adriatic study on treatment approaches, and the use of immunotherapy in both limited and extensive-stage disease. The conversation also delves into the role of PCI, the use of Trilaciclib in extensive stage, and the recent FDA approval of Tarlatamab for small cell lung cancer. Discover the latest advancements and treatment options for small cell lung cancer, including insights on second-line treatments, consolidation radiation, and the management of patients with driver mutations. Dr. Singhi also highlights the importance of patient advocacy groups like the Small Cell Smashers in providing support for individuals with small cell lung cancer. Tune in to this episode for a comprehensive overview of the current treatment landscape for small cell lung cancer and gain valuable insights from Dr. Singhi's expertise in the field. Don't miss out on this informative discussion on the Oncology Brothers podcast!